Angiotensin II (AngII) is a key peptide in cardiovascular homeostasis and is a ligand for the Angiotensin II type 1 and 2 seven transmembrane receptors (AT 1 R and AT 2 R). The AT 1 receptor is a seven-transmembrane (7TM) G protein-coupled receptor (GPCR) mediating the majority of the physiological functions of AngII. The AT 1 R mediates its effects through both G proteindependent and independent signaling, which can be separated by functionally selective agonists. In the present study we investigate the effect of AngII and the β-arrestin biased agonist [SII]AngII on ischemia-reperfusion injury in rat hearts. Isolated hearts mounted in a Langendorff perfused rat heart preparations showed that preconditioning with [SII]AngII reduced the infarct size induced by global ischemia from 46±8.4% to 22±3.4%. In contrast, neither preconditioning with AngII nor postconditioning with AngII or [SII]AngII had a protective effect. Together these results demonstrate a cardioprotective effect of simultaneous blockade of G protein signaling and activation of G protein independent signaling through AT 1 receptors.
Introduction
The renin-angiotensin system (RAS) is a major endocrine regulatory system of cardiovascular physiology and its main effector peptide is angiotensin II (AngII). Most of the known physiological and pathophysiological effects of AngII are mediated by AT 1 [SII]AngII induces a receptor conformation that has limited coupling to G proteins, yet remains able to activate extracellular signal-regulated kinase 1/2 (ERK1/2) through a β-arrestin2 dependent mechanism. This means that in practice [SII]AngII will work as a functional antagonist on G protein mediated signaling while it activates G protein independent pathways [7] [8] [9] 12] . Furthermore, a recent study by Ahn et al., 2009 [13] , demonstrated that β-arrestin2 can facilitate anti-apoptotic signaling through regulation of BAD phosphorylation.
The role of AngII in myocardial ischemia/reperfusion injury has been investigated in the heart [14] [15] [16] [17] [18] . Despite this, its involvement is still not clearly understood. The AngII concentration is reported to increase in the heart after myocardial infarction (MI) and this high AngII milieu is considered deleterious [17, 19, 20] . Several studies have demonstrated a cardioprotective effect of both pharmacological pre-and postconditioning with ACE inhibitors and AT 1 receptor blockers [21] [22] [23] [24] [25] [26] . Today, one of the common clinical treatments of myocardial infarction is also based on ACE inhibitors and AT 1 receptor antagonists [27] , although this acute protection is often precluded by hypotension.
So far no studies have dealt with the role of functional selectivity of AT 1 R in myocardial ischemia/reperfusion. Since [SII] AngII is an almost complete functional antagonist on the Gα q/11 pathway, which is believed to cause the majority of the undesired AngII mediated effects, while preserving cardioprotective AT 1 R signaling, we hypothesized that a biased agonist applied as pre-and/or postconditioning would improve myocardial survival. Therefore, the aim of this study was to analyze the functional consequences of pharmacological preand postconditioning with AngII and [SII]AngII in isolated perfused rat hearts subjected to ischemia/reperfusion.
Materials and Methods

Animals
Male Spraque-Dawley rats (Taconic, Denmark; body weight 409±11g, (no signi�icant difference between groups)) were used. Prior to experiments the animals were acclimated for minimum one week while allowing free access to food and water. The study protocol was approved by the Danish Research Animal Committee, and all procedures were done in accordance with Danish National Committee for Animal Studies guidelines. Langendorff heart preparation Rats were anesthetized subcutaneously with a mixture of midazolam 2.5mg/kg; �luanisone 2.5 mg/ kg; fentanyl citrate 0.08mg/kg) followed by a subcutaneous injection with heparin (1.000 IU/kg). The rats were tracheotomized and ventilated on room air. The chest was opened and the heart was cannulated with immediate transition to retrograde coronary perfusion with a Krebs'-Henseleit (K-H) ringer that contained in mM: NaCl 119.9; KCl 3.3; NaHCO3 25.0; glucose 11.0; MgSO4 1.2; KH2PO4 1.2; CaCl 1.7. The solution was warmed (37°C), and gassed with 95% O 2 , 5% CO 2 to maintain pH at 7.4. The heart was removed from the animal and mounted in a Langendorff perfusion apparatus (Hugo Sachs-Harvard Apparatus GmbH, Germany). This enabled the heart to be perfused at a hydrostatic pressure of app. 60-80mmHg during the whole experiment. In order to facilitate a venous out�low, a small incision was made in the pulmonary artery.
Drugs and chemicals
AngII was used at 100nM and [SII]AngII at 18.7 µM to obtain equal near-saturating receptor occupancies [28, 29] . Drugs were prepared fresh daily by diluting the stock solution in the perfusion buffer.
Functional measurements
The Langendorff perfusion setup allowed continuous recording of left ventricular developed pressure (LVDP) (mmHg), aortic �lowrate (ml/min), aortic pressure (mmHg) and heart rate (BPM) throughout the experiment. LVDP was measured through a �luid-�illed latex balloon (0.06ml, Hugo Sachs-Harvard Apparatus GmbH, Germany) connected to a pressure transducer. The balloon was inserted into the left ventricle through an incision in the left atrium. The volume of the balloon was adjusted to achieve a left ventricular enddiastolic pressure (LveDP) of app. 0±5mmHg. LVDP was calculated as the difference between end-systolic and end-diastolic left ventricular pressure. All data were acquired at a sampling rate of 1 kHz by a 16-channel PowerLab system (ADInstruments, UK) and analyzed using LabChart 7 Pro Software (ADInstruments, UK).
Heart rate was measured as a peak to peak rate analysis of LVDP. Through the whole experiment the heart was submerged in the organ bath containing K-H ringer kept at 37°C. Throughout the experiment perfusion in�low temperature was measured in order to keep it constant.
Perfusion protocols
Spontaneously beating hearts were stabilized for 40 min. After that, hearts were assigned randomly into six groups, each composed by three to six hearts. Control: Hearts in the Control group (Control) (n=6) were subjected to 30 min of global ischemia followed by 120 min of reperfusion in K-H ringer. Ischemic preconditioning: Prior to 30 min of global ischemia, hearts underwent Ischemic preconditioning (IP) (n=3) consisting of two 5-min occlusion periods (global no-�low ischemia) interspersed with 5 min of reperfusion. The 30 min of global ischemia was followed by 120 min of reperfusion in K-H ringer. All protocols are summarized in Fig. 1 .
Quanti�ication of myocardial infarct size
The extent of infarcted myocardium was determined by 2,3,5-triphenyltetrazolium chloride (TTC) staining. After each experiment the heart was rapidly removed from the Langendorff perfusion apparatus, and frozen at -80°C over night. The following day the frozen heart was cut into 2 mm-thick transverse sections, thawed, and incubated in TTC (1% phosphate buffer pH 7.4, 37°C) for 5 min in order to determine the viable and non-viable myocardium. Immediately after staining the tissue slices were �ixed in 4% formalin for 24 h. Next day the heart slices were weighed, and both sides of each slice were scanned using a �latbed scanner (HP Scanjet G4050). The area of infarct and the total area of slices were assessed by planimetry (Image-Tool 2.0 software, NIH, USA). Total infarct size determined as a percentage of total muscle mass (representing Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry total area, AAR) was calculated as the weighted mean of individual slice values:
where AIn is the area of infarct for the slice (n) and Wn is the weight of the respective section (n) and Wtotal is the sum of all the slice weights. Quanti�ication of infarct size was performed by an investigator who was blinded to the different experimental groups.
Exclusion criteria
Hearts were excluded from the study if one of the following criteria was ful�illed:
(1) If the aortic wall was damaged during cannulation leading to an inability to maintain a constant aortic pressure at 60-80mmHg. Eleven rats were excluded due to irreversible VF during reperfusion (Three (IP), three [SII]AngII post, three [SII]AngII pre and two AngII pre). One (Control) rat was excluded due to problems with the TTCstaining.
Statistical analysis
All data are presented as mean±SEM using GraphPad Prism software (San Diego, CA, USA). Comparison of infarct sizes as well as cardiac function and hemodynamic effects of pharmacological preconditioning with AngII and [SII]AngII was performed using one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc test. To compare the effect of treatment on cardiac function and hemodynamics during reperfusion, two-way analysis of variance followed by a Bonferroni post hoc test was performed at stabilization, and 
Results
Hemodynamic parameters and coronary �low Effects of AngII and [SII]
AngII preconditioning on cardiac function. Pharmacological preconditioning with AngII and [SII]AngII on isolated perfused heart preparations was performed to investigate their potential cardioprotective effect. Protocols are shown in Fig.  1 . Prior to global ischemia the changes in hemodynamic parameters due to pharmacological preconditioning was investigated. Coronary �low rate, heart rate, systolic (LVDP) and diastolic (LveDP) function were measured during the different drug preconditioning trials, where 100 nM AngII and 18.7 µM [SII]AngII were used. Values were calculated as the difference between baseline values (during stabilization) and a mean of the last 5 min of 15 min drug treatment. Values were normalized to those of control hearts, which did not receive any drug preconditioning. The hearts that received pharmacological treatment with AngII experienced a reduced coronary �low when compared to Control group (67±10% versus 100±5%, respectively, P<0.05) (Fig. 2) . By contrast the hearts that received [SII]AngII did not exhibit vasoconstriction. Diastolic and systolic function as well as heart rate were similar in all groups at baseline and were not in�luenced signi�icantly by drug administration in either group (Table 1 and Fig. 2) .
Hemodynamic consequences of ischemia. Figure 3 shows the time course for ischemic contracture expressed as a percentage of peak contracture (AngII post: 57±6 mmHg at 18 min). 30 min of global ischemia markedly elevated left ventricular end-diastolic pressure (LveDP) in all experimental groups (Fig. 3 is divided into an A and B part for clarity) . The time to maximal LveDP varied with treatment. At 16 min, the ischemic preconditioned (IP) group (20±6mmHg), the [SII]AngII pre group (35±6mmHg), the AngII pre (49±11mmHg) and the control group (51±7mmHg) reached their maximum. A signi�icant difference in peak contracture was found between control group and IP group (P<0.05). Impaired hemodynamic function after ischemia. Changes in contractile (systolic and diastolic) function after 30 min of global ischemia were investigated to measure the cardioprotective effects of the different treatments. During reperfusion, coronary �low did not resume at pre-ischemic levels, and diastolic and systolic functions were signi�icantly altered ( Fig. 4 and 5) . Figure 4A and 4B show the time course for left ventricular developed pressure (LVDP) expressed as a percentage of baseline values (during stabilization) in each group. At reperfusion, hearts in all groups showed a restricted developed pressure during the 
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Infarct size data
The extent of infarct size after ischemia-reperfusion (I/R) was determined by a 2,3,5-triphenyltetrazolium chloride (TTC) staining. In the control group, 30 min of global no-�low normothermic ischemia followed by 120 min of reperfusion resulted in an infarct size of 46±8.4% of the total area. The infarct sizes in the different groups are summarized in �igure 6 and a representative visualization of ischemic hearts is shown in Figure 7 .
Protection was achieved by ischemic preconditioning (IP). Here, the infarct size was signi�icantly reduced to 14±5.2% compared to the 46±8.4% observed in the control group (P<0.05) (Fig. 6) . A signi�icant reduction was also achieved when 18. 
Discussion
Ischemic preconditioning (IP) is a well established technique to induce cardioprotection [30, 31] . Consistent with previous studies, our experiments also show signi�icant improvement of relaxation and systolic function (Fig. 4 and 5) , as well as reduced myocardial infarction (Fig. 6 ) when short episodes of no-re�low ischemia were introduced prior to prolonged ischemia [30, 31] .
No signi�icant changes in post-ischemic recovery of cardiac contractility were observed by pharmacological AngII treatment (Fig. 4 and 5) . This was the case for both pre-and postconditioning and the current �indings correlate with what previous studies have seen [17, 21] . In 2000, Zhu et al., investigated the comparative effects of pretreatment with the ACE inhibitor, captopril, and the AT 1 receptor blocker, losartan, on myocardial infarct size. Sprague-Dawley rats were given either captopril or losartan 10 weeks prior to I/R studies. Myocardial I/R was then induced in a model of left anterior descending coronary artery (LAD) occlusion (17min) and reperfusion (120min). They found that myocardial infarct size was signi�icantly smaller in the losartan and captopril groups than in the control group [21] . Several other experimental models have similarly demonstrated the protective effects of both ACE inhibitors and AT 1 R antagonists in I/R studies [22, 24, 26] . There is thus solid evidence of a deleterious effect connected with particularly G protein-dependent signaling from the AT 1 R in the setting of Ischemia and Reperfusion. To investigate whether selective G protein-independent pathways are more bene�icial in the ischemic heart, we included pre-and postconditioning protocols with the selective β-arrestin-biased AngII analogue [SII]AngII. In contrast to AngII, the peptide ligand [SII]AngII is able to induce a receptor active conformation with very limited ability to activate G proteins, yet capable of activating ERK 1/2 by the β-arrestin2 pathway [7] [8] [9] 32] .
Pre-ischemic measurements revealed that presence of AngII in the perfusate caused vasoconstriction to decrease �low rates by 23% relative to controls.
[SII]AngII treatment in contrast did not in�luence any of the measured hemodynamic parameters (Fig. 2) . These �indings support the notion that acute regulation of blood pressure by the AT 1 R is caused by G protein stimulated Ca 2+ mobilization and is not (directly) affected by β-arrestin dependent signaling [33] .
The constriction of coronary arteries seen with AngII perfusion is intuitively not desirable in the aftermath of a coronary occlusion, but did not lead to an increase in �inal infarct size (48±7%) (Fig. 6 ). Though we do not demonstrate deleterious effects of AngII in this isolated test of short-term AngII stimulation in a global ischemic model, it may be so when factors like partial reperfusion and collateral compensation are in play. Preconditioning with isolated G protein-independent AT 1 R stimulation was evaluated with [SII]AngII, and induced a signi�icant reduction in infarct size (22±3%) and a tendency towards superior recovery in developed pressure (LVDP and LVeDP) as compared to the control group. Similar testing of [SII]AngII in the postconditioning protocol had no signi�icant effect on infarct size, but by contrast to AngII did not entail reduction of coronary �lowrates.
These results corroborate previous reports that AT 1 R blockers mediate cardioprotective effects through inhibition of deleterious G protein signaling. Futher to this notion, preservation of G protein-independent signaling (β-arrestin2-dependent signaling) has previously been indicated to induce cardioprotective signaling [13, 34, 35] . To further support an antiapoptotic role of β-arrestin signaling, we have found [SII]AngII to inhibit caspase-3 cleavage in isolated cardio-myocytes exposed to apoptotic conditions (data not shown).
Currently Trevena Inc is developing agonists with functional selectivity for β-arrestin signaling (TRV027) for the treatment of acute myocardial infarction, and in two recent studies another potent, selective β-arrestin biased ligand of AT 1 R (TRV120027) increased cardiac performance through a reduced mean arterial pressure and preserved cardiac stroke volume [34, 35] . However, these studies did not perform investigations in relation to I/R.
In summary, the present study establishes that pharmacological preconditioning with the functionally selective AngII analogue [SII]AngII induces cardioprotection as revealed by a signi�icant reduction in myocardial infarct sizes after exposure to ischemic reperfusion. In contrast, pharmacological pre-and postconditioning with AngII does not alter myocardial infarct size. Together these �indings strongly indicate that AT 1 receptor mediated β-arrestin
